Last update 21 Nov 2024
JNJ-80948543
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Trispecific T-cell engager (TriTE) |
Synonyms + [2] |
Target |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors), CD79B inhibitors(B-cell antigen receptor complex-associated protein beta chain inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
6
Clinical Trials associated with JNJ-80948543A Phase 1b Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers (TCEs) in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoid (R/R B-Cell NHL) Malignancies
A Phase Ib study of JNJ-80948543 in combination with other CD3 T-cell engagers in participants with relapsed/refractory B-cell non-Hodgkin lymphoid malignancies
一项在NHL和CLL受试者中开展的JNJ-80948543 T细胞重定向抗体的I期、首次人体研究
[Translation] A Phase I, First-in-Human Study of the JNJ-80948543 T-Cell Redirecting Antibody in Subjects with NHL and CLL
100 Clinical Results associated with JNJ-80948543
Login to view more data
100 Translational Medicine associated with JNJ-80948543
Login to view more data
100 Patents (Medical) associated with JNJ-80948543
Login to view more data
100 Deals associated with JNJ-80948543
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| B-Cell Lymphoma | Phase 1 | JP | 18 Aug 2022 | |
| B-Cell Lymphoma | Phase 1 | PL | 18 Aug 2022 | |
| B-Cell Lymphoma | Phase 1 | IL | 18 Aug 2022 | |
| B-Cell Lymphoma | Phase 1 | FR | 18 Aug 2022 | |
| B-Cell Lymphoma | Phase 1 | IL | 18 Aug 2022 | |
| B-Cell Lymphoma | Phase 1 | AU | 18 Aug 2022 | |
| B-Cell Lymphoma | Phase 1 | AU | 18 Aug 2022 | |
| B-Cell Lymphoma | Phase 1 | DK | 18 Aug 2022 | |
| B-Cell Lymphoma | Phase 1 | DK | 18 Aug 2022 | |
| B-Cell Lymphoma | Phase 1 | CN | 18 Aug 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free